The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Size: px
Start display at page:

Download "The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only."

Transcription

1 The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall potential risks or benefits of a product which are based on an evaluation of an entire research program. Before prescribing any Takeda products, healthcare professionals should consult prescribing information for the product approved in their country.

2 STUDY SYNOPSIS Name of Sponsor/Company: Takeda Pharmaceutical Company Limited Name of Product: Takepron Intravenous 30 mg Name of Active Ingredient: Lansoprazole Official title: Takepron Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate] Brief title: Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate] Objectives: The objective of this study was to evaluate the safety (frequency of adverse events) and efficacy (hemostatic effect, rate of rebleeding after confirmation of hemostasis) of administration of Takepron Intravenous 30 mg (hereinafter referred to as the drug). Safety: Confirmation of the frequency of adverse events (symptoms, frequency, and seriousness) during the observation period Efficacy: (i) Hemostatic effect Evaluation of the time to hemostasis confirmed by endoscopy after the start of treatment with the drug (ii) Rebleeding rate Evaluation of the presence or absence of rebleeding during treatment with the drug and 8 weeks after the completion of treatment with the drug in patients for whom hemostasis was confirmed by endoscopy after the start of treatment with the drug Study design: Observational study Sample size: 1120 patients Study population:

3 Patients with the following diseases for whom oral administration is not feasible: Gastric ulcer, duodenal ulcer, acute stress ulcer, and acute gastric mucosal lesion (all of which should be accompanied by bleeding) Study period: January 29, 2007 to March 31, 2010 Definition of Outcome: Primary Endpoint <Safety> Frequency of adverse drug reactions Secondary Endpoints <Efficacy> Statistical analysis: <Safety> For adverse drug reactions that occur during the observation period, rate of onset (hereinafter referred to as frequency), the number of patients, the number of events, and types of events were tabulated. In addition, the frequency of adverse drug reactions was tabulated by seriousness, time to onset, and outcome. <Efficacy> In patients for whom hemostatic effect was observed, the number of patients analyzed, the number of patients demonstrating each hemostatic effect, and the efficacy rate were tabulated. In patients for whom hemostasis was confirmed during treatment with the drug, the number of patients for whom hemostasis was confirmed during treatment, the number of patients who experienced rebleeding after hemostasis during treatment, and the rebleeding rate were tabulated. In patients for whom hemostasis was confirmed at the end of treatment with the drug and for

4 whom the presence or absence of hemostasis was confirmed after the completion of treatment with the drug, stratification was performed according to the time to rebleeding: data on the time to rebleeding was obtained from the results of the presence or absence of hemostasis during the 56 days after the completion of treatment with the drug, and the number of patients for whom hemostasis was confirmed, the number of patients who experienced rebleeding after hemostasis, and the cumulative rebleeding rate were tabulated by stratum (days). The cumulative rebleeding rate for the period from the date of completion of treatment with the drug to the date rebleeding was observed was calculated using the Kaplan-Meier method. Summary of Results: 1. Safety (1) Occurrence of adverse drug reactions - Adverse drug reactions were observed in 35 (3.23%, 42 events) out of 1084 patients (safety assessment population). - The most common adverse drug reactions (3 or more events) were gastric hemorrhage (7 events), diarrhea (3 events), hepatic function abnormal (3 events), liver disorder (3 events), pyrexia (3 events), and white blood cell count decreased (3 events). (2) Occurrence of serious adverse drug reactions - Serious adverse drug reactions were reported in 9 patients (0.83%, 13 events). - The serious adverse drug reactions reported were gastric hemorrhage (4 events), insomnia (1 event), restlessness (1 event), depressive symptom (1 event), depressed level of consciousness (1 event), diarrhea (1 event), gastric ulcer hemorrhage (1 event), cholangitis (1 event), muscular weakness (1 event), and white blood cell count decreased (1 event). (3) Time to onset of adverse drug reactions - 39 out of the 42 adverse drug reactions occurred within 14 days after the start of treatment. 2. Efficacy - Among the 1052 patients for whom hemostatic effects were observed, the efficacy rate ("markedly improved" + "moderately improved" + "slightly improved") was 90.3% (950/1052 patients). - Among the 898 patients for whom hemostatic effect was confirmed by endoscopy,

5 the efficacy rate ("markedly improved" + "moderately improved" + "slightly improved") was 91.6% (821/896 patients). - Among the 819 patients for whom hemostasis was confirmed at any time during treatment with the drug, the rebleeding rate after hemostasis during treatment with the drug was 1.1% (9/819 patients). - Among the 745 patients for whom hemostasis was confirmed by endoscopy at any time during treatment with the drug, the rebleeding rate after hemostasis during treatment with the drug was 1.2% (9/745 patients). - Among the 497 patients for whom hemostasis was confirmed at the final evaluation point during treatment with the drug and for whom the presence or absence of hemostasis was confirmed after the completion of treatment with the drug, the cumulative rebleeding rate 8 weeks after the completion of treatment with the drug was 5.8% and 19 out of 24 patients experienced rebleeding within 7 days after the completion of treatment with the drug. - Among the 389 patients for whom hemostasis was confirmed by endoscopy at the final evaluation point during treatment with the drug and for whom the presence or absence of hemostasis was confirmed after the completion of treatment with the drug, the cumulative rebleeding rate 8 weeks after the completion of treatment with the drug was 7.1% and 17 out of 22 patients experienced rebleeding within 7 days after the completion of treatment with the drug. Date of the report: October 2, 2015

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Title of Study: Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Title of Study: Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil SYNOPSIS Name of Sponsor/Company Name of Finished Product REMINYL Name of Active Ingredient(s) Galantamine hydrobromide Issue Date: 18 October 2013 Protocol No.: Title of Study: Evaluation of Efficacy

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Protonix for bleeding

Protonix for bleeding Protonix for bleeding The Borg System is 100 % Protonix for bleeding Dec 17, 2010. The ideal pharmacologic therapy for highrisk patients with acute peptic ulcer bleeding is an IV PPI started immediately

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

CLINICAL STUDY REPORT SYNOPSIS

CLINICAL STUDY REPORT SYNOPSIS CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

ACG Clinical Guideline: Management of Patients with Ulcer Bleeding

ACG Clinical Guideline: Management of Patients with Ulcer Bleeding ACG Clinical Guideline: Management of Patients with Ulcer Bleeding Loren Laine, MD 1,2 and Dennis M. Jensen, MD 3 5 1 Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut,

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Hydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109

Hydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-712 Volume: Hydrocodone/Acetaminophen Extended-Release Name

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Kathy P. Bull-Henry, MD, FACG Dr. Bull-Henry has indicated no relevant financial relationships. Don t Waste Time With No Chance to See

Kathy P. Bull-Henry, MD, FACG Dr. Bull-Henry has indicated no relevant financial relationships. Don t Waste Time With No Chance to See Don t Waste Time with No Chance to See Kathy P. Bull-Henry, MD, FACG Dr. Bull-Henry has indicated no relevant financial relationships. Don t Waste Time With No Chance to See Kathy Bull-Henry, MD, FACG

More information

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

VARICEAL BLEEDING. Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta.

VARICEAL BLEEDING. Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta. VARICEAL BLEEDING Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta Disclosures: None OUTLINE Pathophysiology of portal hypertension Splanchnic

More information

Product: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1

Product: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1 Date: 02 April 2014 Page 1. 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Omecamtiv mecarbil injection Name of Active Ingredient: Omecamtiv mecarbil (AMG 423) Title of Study: A double-blind,

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

A bleeding ulcer: What can the GP do? Gastrointestinal bleeding is a relatively common. How is UGI bleeding manifested? Who is at risk?

A bleeding ulcer: What can the GP do? Gastrointestinal bleeding is a relatively common. How is UGI bleeding manifested? Who is at risk? Focus on CME at the University of British Columbia A bleeding ulcer: What can the GP do? By Robert Enns, MD, FRCP Gastrointestinal bleeding is a relatively common disorder affecting thousands of Canadians

More information

2.0 Synopsis. Adalimumab M Clinical Study Report R&D/13/416. Individual Study Table Referring to Part of Dossier: Volume:

2.0 Synopsis. Adalimumab M Clinical Study Report R&D/13/416. Individual Study Table Referring to Part of Dossier: Volume: 2.0 Synopsis AbbVie Inc. Name of Study Drug: Humira Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title of Study:

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

HM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics>

HM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics> The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Summary of product characteristics (SmPC)

Summary of product characteristics (SmPC) Summary of product characteristics (SmPC) What is it and what does it contain? An agency of the European Union Table of contents 1.What is the summary of product characteristics (SmPC)? 2.Where SmPC information

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Gastrointestinal bleeding: the management of acute upper gastrointestinal bleeding 1.1 Short title Acute upper GI bleeding

More information

532.6 (chronic or unspecified duodenal

532.6 (chronic or unspecified duodenal Supplementary table 1: ICD-9 and ICD-10 codes used for the identification of major bleeding and endoscopy Bleeding episode type ICD-9 codes ICD-10 codes Intracranial 430 (Subarachnoid), 431 (intracerebral),

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

1. Comparative effectiveness of vedolizumab

1. Comparative effectiveness of vedolizumab Cost-effectiveness of vedolizumab (Entyvio ) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were

More information

R (paliperidone palmitate) Clinical Study Report R SCA-3004

R (paliperidone palmitate) Clinical Study Report R SCA-3004 SYNOPSIS Name of Sponsor/Company Janssen Scientific Affairs, LLC Name of Finished Product INVEGA SUSTENNA Name of Active Ingredient(s) Status: Approved Date: 10 March 2014 Prepared by: Janssen Scientific

More information

Immediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020

Immediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Acute variceal bleeding management of, 251 262 balloon tamponade of esophagus in, 257 258 endoscopic therapies in, 255 257. See also Endoscopy,

More information

ABC/3TC/ZDV ABC PBO/3TC/ZDV

ABC/3TC/ZDV ABC PBO/3TC/ZDV The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Intragastric ph With Oral vs Intravenous Bolus Plus Infusion Proton- Pump Inhibitor Therapy in Patients With Bleeding Ulcers

Intragastric ph With Oral vs Intravenous Bolus Plus Infusion Proton- Pump Inhibitor Therapy in Patients With Bleeding Ulcers Intragastric ph With Oral vs Intravenous Bolus Plus Infusion Proton- Pump Inhibitor Therapy in Patients With Bleeding Ulcers LOREN LAINE, ABBID SHAH, and SHAHROOZ BEMANIAN Division of Gastrointestinal

More information

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal

More information

Sponsor/Company: sanofi-aventis Drug substance: Elitek/Fasturtec (rasburicase, SR29142)

Sponsor/Company: sanofi-aventis Drug substance: Elitek/Fasturtec (rasburicase, SR29142) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: sanofi-aventis Drug

More information

This was a multi-center study conducted at 44 study centers. There were 9 centers in the United States and 35 centers in Europe.

This was a multi-center study conducted at 44 study centers. There were 9 centers in the United States and 35 centers in Europe. Protocol CAM307: A Phase 3 Study to Evaluate the Efficacy and Safety of Frontline Therapy with Alemtuzumab (Campath ) vs Chlorambucil in Patients with Progressive B-Cell Chronic Lymphocytic Leukemia These

More information

Referring to Part of Dossier: Volume: Page:

Referring to Part of Dossier: Volume: Page: Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

B Barrett neoplasia, early, endoscopic mucosal resection of, in Europe, 297

B Barrett neoplasia, early, endoscopic mucosal resection of, in Europe, 297 Note: Page numbers of article titles are in boldface type. A Achalasia, treatment of, history of, 258 259 Achalasia myotomy, 270 Adenocarcinomas, endoscopic management of, in Asia, 289 290 B Barrett neoplasia,

More information

Product: Denosumab (AMG 162) Abbreviated Clinical Study Report: (Extension Phase Results) Date: 24 August 2010 Page Page 2 of 2 of

Product: Denosumab (AMG 162) Abbreviated Clinical Study Report: (Extension Phase Results) Date: 24 August 2010 Page Page 2 of 2 of Product: Denosumab (MG 162) bbreviated Clinical Study Report: 20040114 (Extension Phase Results) Date: 24 ugust 2010 Page Page 2 of 2 of 1314 55 2. SYNOPSIS Name of Sponsor: mgen Inc. Name of Finished

More information

Billing and Coding Information

Billing and Coding Information Billing and Coding Information The information provided is for educational purposes only. The healthcare provider is fully responsible for billing and coding determinations. INDICATIONS Injectafer (ferric

More information

TXA: NOT JUST A ONE TRICK PONY TERRY MCGOVERN DO, MPH VITUITY, ST JOHN S REGIONAL MEDICAL CENTER, OXNARD, CA

TXA: NOT JUST A ONE TRICK PONY TERRY MCGOVERN DO, MPH VITUITY, ST JOHN S REGIONAL MEDICAL CENTER, OXNARD, CA TXA: NOT JUST A ONE TRICK PONY TERRY MCGOVERN DO, MPH VITUITY, ST JOHN S REGIONAL MEDICAL CENTER, OXNARD, CA DISCLOSURES I have no relevant financial relationships with the manufacturer(s) of any commercial

More information

Principal Investigator: Robert J. Jones, MD, Beatson Cancer Center, 1053 Great Western Road, Glasgow; United Kingdom

Principal Investigator: Robert J. Jones, MD, Beatson Cancer Center, 1053 Great Western Road, Glasgow; United Kingdom SYNOPSIS Issue Date: 14 October 2010 Document No.: EDMS-ERI-13494974:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Protocol No.: COU-AA-BE Cougar Biotechnology, Inc.

More information

WATCHMAN PROTECT AF Study Rev. 6

WATCHMAN PROTECT AF Study Rev. 6 WATCHMAN PROTECT AF Study Rev. 6 Protocol Synopsis Title WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation (PROTECT AF) Sponsor Atritech/Boston Scientific

More information

Clinical Management of Obscure- Overt Gastrointestinal Bleeding. Presented by Dr. 張瀚文

Clinical Management of Obscure- Overt Gastrointestinal Bleeding. Presented by Dr. 張瀚文 Clinical Management of Obscure- Overt Gastrointestinal Bleeding Presented by Dr. 張瀚文 Definition Obscure: : hard to understand; not clear. Overt: : public; not secret. Occult: : hidden from the knowledge

More information

Sponsor / Company: Sanofi Drug substance(s): SSR103371

Sponsor / Company: Sanofi Drug substance(s): SSR103371 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Synopsis (C1034T02) CNTO 95 Module 5.3 Clinical Study Report C1034T02

Synopsis (C1034T02) CNTO 95 Module 5.3 Clinical Study Report C1034T02 Module 5.3 Protocol: EudraCT No.: 2004-002130-18 Title of the study: A Phase 1/2, Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human

More information

Proton Pump Inhibitors. Description

Proton Pump Inhibitors. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors

More information

Final Clinical Study Report. to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI463110

Final Clinical Study Report. to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI463110 BMS-475 AI463 Name of Sponsor/Company: Bristol-Myers Squibb Individual Study Table Referring to the Dossier For National Authority Use Only) Name of Finished Product: Baraclude Name of Active Ingredient:

More information

On-Call Upper GI Bleeding. Upper Gastrointestinal Bleeding

On-Call Upper GI Bleeding. Upper Gastrointestinal Bleeding On-Call Upper GI Bleeding John R Saltzman MD, FACG Director of Endoscopy Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Upper Gastrointestinal Bleeding 300,000000 hospitalizations/year

More information

Soleus 75 (6 ml) 0 (6 ml) 75 (6 ml. Tibialis posterior 75 (6 ml) 0 (6 ml) 75 (6 ml) Total 300 (24 ml) 0 (24 ml) 300 (24 ml) Dose: U (solution volume)

Soleus 75 (6 ml) 0 (6 ml) 75 (6 ml. Tibialis posterior 75 (6 ml) 0 (6 ml) 75 (6 ml) Total 300 (24 ml) 0 (24 ml) 300 (24 ml) Dose: U (solution volume) Study No.: BTX108512 Title: A Multicenter Study to Evaluate the Efficacy and Safety in Patients with Post-Stroke lower Limb Spasticity Receiving a Double-Blind, -Controlled GSK1358820 Treatment Followed

More information

a newsletter detailing appropriate indications of IV PPI was sent to physicians;

a newsletter detailing appropriate indications of IV PPI was sent to physicians; Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions Kaplan G G, Bates D, McDonald D, Panaccione R, Romagnuolo J Record Status This is a critical abstract of an

More information

Genentech Statement on Counterfeit Drug Labeled as Avastin (bevacizumab) in the United States

Genentech Statement on Counterfeit Drug Labeled as Avastin (bevacizumab) in the United States Genentech Statement on Counterfeit Drug Labeled as Avastin (bevacizumab) in the United States SOUTH SAN FRANCISCO, Calif. February 14, 2012 Roche and Genentech have been informed that a counterfeit product,

More information

CLINICAL STUDY REPORT SYNOPSIS

CLINICAL STUDY REPORT SYNOPSIS CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-6511694:4.0 Name of Sponsor/Company Johnson & Johnson Pharmaceutical Research & Development Name of Finished Product Name of Active Ingredient Protocol

More information

This was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.

This was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe. Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied

More information

Individual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138

Individual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138 Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Atazanavir () Individual Study Table Referring to the Dossier (For National Authority Use Only)

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

GASTROINESTINAL BLEEDING. Dr.Ammar I. Abdul-Latif

GASTROINESTINAL BLEEDING. Dr.Ammar I. Abdul-Latif GASTROINESTINAL BLEEDING Dr.Ammar I. Abdul-Latif CLASSIFICATION OF G.I.BLEEDING GIB Appearance Acuity Site Apparent Acute Upper Obscure Chronic Lower UPPER&LOWER G.I.BLEEDING CAUSES OF UPPER G.I. BLEEDING

More information

Individual Study Table Referring to Part of the Dossier. Volume:

Individual Study Table Referring to Part of the Dossier. Volume: SYNOPSIS Name of Sponsor/Company Protocol no.: CR002665 Title of Study: A Phase II, Randomized, Investigator-Blinded, Parallel-Group Pilot Study Evaluating the Safety, Palatability and Efficacy of Four

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

Improved risk assessment in upper GI bleeding

Improved risk assessment in upper GI bleeding EDITORIAL Improved risk assessment in upper GI bleeding Acute upper GI bleeding is the most common GI emergency, with a reported incidence in various epidemiological studies ranging from 50 to over 100

More information

Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy

Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy Yen et al. BMC Gastroenterology 2012, 12:66 RESEARCH ARTICLE Open Access Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful

More information

Acute Upper Gastrointestinal Hemorrhage Surgical Perspective. Dr.J.H.Barnard Dept. of Surgery PAH

Acute Upper Gastrointestinal Hemorrhage Surgical Perspective. Dr.J.H.Barnard Dept. of Surgery PAH Acute Upper Gastrointestinal Hemorrhage Surgical Perspective Dr.J.H.Barnard Dept. of Surgery PAH Introduction: AGH is a leading cause of admissions into ICU. Overall mortality 5-12%, but increases to 40%

More information

Tocilizumab Guided Questionnaire Gastrointestinal Perforation and Related Events

Tocilizumab Guided Questionnaire Gastrointestinal Perforation and Related Events Tocilizumab Guided Questionnaire Gastrointestinal Perforation and Related Events AER: Site : Local Case ID: Patient Date of Birth (dd-mmm-yyyy): Patient ID/Initials: Patient Gender: M F Patient Weight

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

SYNOPSIS. Issue Date: 25 Oct 2011

SYNOPSIS. Issue Date: 25 Oct 2011 SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:

More information

Surgery while taking Protonix? 1,368 conversations on the web about experiences with taking Protonix before or after having a Surgery.

Surgery while taking Protonix? 1,368 conversations on the web about experiences with taking Protonix before or after having a Surgery. Surgery while taking Protonix? 1,368 conversations on the web about experiences with taking Protonix before or after having a Surgery. Everything you ever wanted to know about gastric sleeve surgery. What

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before

More information

Summary of the study protocol of the FLOT3-Study

Summary of the study protocol of the FLOT3-Study Summary of the study protocol of the FLOT3-Study EudraCT no. 2007-005143-17 Protocol Code: S396 Title A Prospective Multicenter Study With 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients

More information

Factorial Study Design 07/18/12

Factorial Study Design 07/18/12 Disclaimer: The following information is fictional and is only intended for the purposes of illustrating key concepts for results data entry in the Protocol Registration System (PRS). Example Factorial

More information

Prevpac Pylera Omeclamox-Pak

Prevpac Pylera Omeclamox-Pak Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.21 Subject: -Pak Page: 1 of 5 Last Review Date: September 20, 2018 -Pak Description (lansoprazole,

More information

CLINICAL STUDY REPORT SYNOPSIS

CLINICAL STUDY REPORT SYNOPSIS CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-7176909:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient Protocol No.: CR002350 Johnson & Johnson Pharmaceutical Research

More information

EGD Data Collection Form

EGD Data Collection Form Sociodemographic Information Type Zip Code Gender Height (in inches) Race Ethnicity Inpatient Outpatient Male Female Birth Date Weight (in pounds) American Indian (Native American) or Alaska Native Asian

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 5 January 2011

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 5 January 2011 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 5 January 2011 Review of the dossier of the proprietary drugs included on the list of reimbursable medicines for a

More information

Patient Registration Form

Patient Registration Form Patient Registration Form Name: Today s Date: FIRST MIDDLE LAST Home Address: City: State: Zip: Telephone: ( ) Birthdate: Age: Occupation: SSN: Employer: Years There: Employer s Address: City: State: Zip:

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

DRUG REVIEW. Drug Information Center, Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, WA

DRUG REVIEW. Drug Information Center, Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, WA DRUG REVIEW Peptic Ulcer Bleeding Following Therapeutic Endoscopy: A New Indication for Intravenous Esomeprazole Danial E. Baker, PharmD, FASCP, FASHP Drug Information Center, Department of Pharmacotherapy,

More information

Synopsis of Study Results

Synopsis of Study Results Synopsis of Study Results Name of Sponsor/Company Name of Finished Product (if approved) Name of Active Ingredient Title of Study Daiichi Sankyo Company, Limited Gabalon Intrathecal Injection baclofen

More information

Gastroenterology. Certification Examination Blueprint. Purpose of the exam

Gastroenterology. Certification Examination Blueprint. Purpose of the exam Gastroenterology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified gastroenterologist

More information

GI Coding Updates. Rhonda Buckholtz, CPC, CPCI, CPMS, CRC, CDEO, CHPSE, CGSC, COBGC, CENTC, CPEDC

GI Coding Updates. Rhonda Buckholtz, CPC, CPCI, CPMS, CRC, CDEO, CHPSE, CGSC, COBGC, CENTC, CPEDC GI Coding Updates Rhonda Buckholtz, CPC, CPCI, CPMS, CRC, CDEO, CHPSE, CGSC, COBGC, CENTC, CPEDC Copyright/Disclaimer 2014 AAPC text CPT copyright 2016 American Medical Association. All rights reserved.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Abdominal Pain in a Young Aviator

Abdominal Pain in a Young Aviator Abdominal Pain in a Young Aviator Calen N. Wherry, MD, MPH Maj, USAF, MC, FS Peter A. Baldwin, MD, MBA, MPH Capt, USAF, MC, FS USAF School of Aerospace Medicine WPAFB, OH RAM 2013 Distribution A: Approved

More information

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Advil / Ibuprofen

More information

Surgery for Complications of Peptic Ulcer Disease (Definitive Treatment)

Surgery for Complications of Peptic Ulcer Disease (Definitive Treatment) Surgery for Complications of Peptic Ulcer Disease (Definitive Treatment) Amid Keshavarzi, MD UCHSC Grand Round 3/20/2006 Department of Surgery Introduction Epidemiology Pathophysiology Clinical manifestation

More information

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors

More information

SYNOPSIS. Issue Date: 31 July 2013

SYNOPSIS. Issue Date: 31 July 2013 SYNOPSIS Issue Date: 31 July 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development, LLC YONDELIS Trabectedin (R279741) Protocol No.: ET743-OVC-1003

More information

Shou Jiang Tang, MD, FASGE. Director of Endoscopic Research Professor in Medicine

Shou Jiang Tang, MD, FASGE. Director of Endoscopic Research Professor in Medicine Shou Jiang Tang, MD, FASGE Director of Endoscopic Research Professor in Medicine Through-the-scope clipping devices Over-the-scope clipping devices First reported clipping device Hayshi T, Yonezawa M,

More information

Omeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.

Omeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty. Omeprazole 10mg Name, Restriction, Manner of administration and form omeprazole 10 mg enteric tablet, 30 (8332M) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form omeprazole

More information

Health technology The use of four different combined treatments for Helicobacter pylori (H. pylori) infection. These were:

Health technology The use of four different combined treatments for Helicobacter pylori (H. pylori) infection. These were: Tratamiento de la infeccion por Helicobacter pylori en pacientes con ulcera duodenal: estudio de costo-beneficio [Treatment of Helicobacter pylori infection in patients with duodenal ulcer: a cost-benefit

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for highrisk bleeding ulcers: systematic review and meta-analysis. JAMA Intern Med. Published

More information